RAC 1.78% $1.43 race oncology ltd

General Comments / Chat, page-6436

  1. 8,429 Posts.
    lightbulb Created with Sketch. 1386
    Wombat you're right in the sense that peripheral IV isn't under consideration for the AML EMD trial.

    But central line would slow down the breast cancer trial so much that's it's better to wait until peripheral IV is available. Which is the point that the original poster had overlooked.

    I'm glad you're following the debates and contributing.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.